Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABT
HoldFallen FavouriteAbbott Laboratories · Healthcare · United States · $194.6B · Avg Vol: $807M/d
COMPANY DESCRIPTION
Abbott Laboratories is a diversified global healthcare company engaged in the discovery, development, manufacturing, and sale of a broad array of medical products across four segments: Diagnostics, Medical Devices, Nutritionals, and Established Pharmaceuticals. The company's formidable competitive moat stems from its diverse product portfolio addressing critical health needs, robust R&D pipeline, strong global brand recognition for products like FreeStyle Libre, and extensive regulatory and manufacturing expertise. This broad reach and innovation secure its leadership across multiple essential healthcare markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.7B | 40.1B | 42.0B | 44.3B | 0.5% | 46.6B | 50.3B | 54.6B | 11.0% |
| EPS | 3.99 | 3.30 | 7.74 | 3.76 | -2.0% | 3.09 | 4.03 | 4.42 | 8.5% |
| Shares | 1.7B | 1.7B | 1.7B | 1.7B | -0.1% | 1.7B | — | — | — |
| Debt | 17.7B | 15.6B | 15.0B | 13.9B | -7.9% | 32.7B | — | — | — |
| Equity | 36.7B | 38.6B | 47.7B | 52.1B | 12.4% | — | — | — | — |
| Op CF | 9.6B | 7.3B | 8.6B | 9.6B | -0.1% | 9.9B | — | — | — |
| Inv CF | -1.7B | -3.1B | -2.3B | -2.4B | — | — | — | — | — |
| Fin CF | -7.6B | -7.1B | -5.4B | -6.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABT | Abbott Laboratories(you) | $194.6B | 61 | Hold |
| SYK | Stryker Corporation | $126.8B | 58 | Hold |
| SHL.DE | Siemens Healthineers AG | $51.3B | 63 | Hold |
| EW | Edwards Lifesciences Corporation | $52.0B | 65 | Buy |
| MDT | Medtronic plc | $116.8B | 82 | Strong Buy |
| BSX | Boston Scientific Corporation | $67.9B | 48 | Hold |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
| 300760.SZ | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | $29.6B | 63 | Hold |
| DXCM | DexCom, Inc. | $34.3B | 84 | Strong Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
Peer medians: ROE 2.9% · P/E 24.3x · Gross margin 52.6%